Literature DB >> 25201141

Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.

Tony He1, Mark E Cooper1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25201141     DOI： 10.1038/nrneph.2014.162

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Wouter B A Eijkelkamp; Zhongxin Zhang; Giuseppe Remuzzi; Hans-Henrik Parving; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Gilbert W Gleim; Matthew R Weir; Barry M Brenner; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 10.121

2.  The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.

Authors:  Omar M E Abdel-Salam; Ayman R Baiuomy; Siham M El-Shenawy; Mahmoud S Arbid
Journal:  Pharmacol Res       Date:  2003-04       Impact factor: 7.658

Review 3.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 4.  Pentoxifylline for diabetic kidney disease.

Authors:  Dan Shan; Hong Mei Wu; Qi Yuan Yuan; Jun Li; Rong Le Zhou; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

5.  Changes in diabetes-related complications in the United States, 1990-2010.

Authors:  Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

6.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Jesús Chahin; María L Méndez; Eduardo Gallego; Manuel Macía; Nieves del Castillo; Antonio Rivero; María A Getino; Patricia García; Ana Jarque; Javier García
Journal:  J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 10.121

7.  Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Authors:  Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612

8.  Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes.

Authors:  C C Cowie; F K Port; R A Wolfe; P J Savage; P P Moll; V M Hawthorne
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

Review 9.  Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.

Authors:  P Vejakama; A Thakkinstian; D Lertrattananon; A Ingsathit; C Ngarmukos; J Attia
Journal:  Diabetologia       Date:  2011-12-22       Impact factor: 10.122
  9 in total
  3 in total

Review 1.  Cyclic nucleotide signalling in kidney fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

Review 2.  Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.

Authors:  Yung-Ming Chen; Wen-Chih Chiang; Shuei-Liong Lin; Tun-Jun Tsai
Journal:  J Biomed Sci       Date:  2017-11-13       Impact factor: 8.410

3.  Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.

Authors:  Hsun Yang; Shiun-Yang Juang; Kuan-Fu Liao; Yi-Hsin Chen
Journal:  Nutrients       Date:  2019-09-12       Impact factor: 5.717
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.